The meta‐analysis results revealed that GDF15 levels were significantly lower in healthy controls compared with CRC patients (pooled SMD = 1.08, 95% CI: 0.56–1.59; P < 0.001), and significant heterogeneity was found: I2 = 97.8% (Fig. 3). This evidence concerns the gene GDF15 and colorectal carcinoma.